Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?
Lynn Roy et al, 2018, Cancers CrossRef
Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways
Mi-Ae Kang et al, 2019, Cancers CrossRef
Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity
Chin-Jui Wu et al, 2019, Cancers CrossRef
Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy
Yanfei Yang et al, 2020, Front. Cell Dev. Biol. CrossRef
High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Yang Song et al, 2020, Disease Markers CrossRef
Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer
Hee-Sung Ahn et al, 2020, Cancers CrossRef
Krupple-Like Factor 5 is a Potential Therapeutic Target and Prognostic Marker in Epithelial Ovarian Cancer
Abdul K. Siraj et al, 2020, Front. Pharmacol. CrossRef
Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity
Janisha Silva Raju et al, 2021, Diagnostics CrossRef
A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer
Samantha M. Perez et al, 2021, Cells CrossRef
Oncostatin M Receptor–Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth
Anjali Geethadevi et al, 2021, Cancer Res CrossRef
Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review.
Teklie Mengie Ayele et al, 2022, J Inflamm Res CrossRef
The “Sweet Spot” of Targeting Tumor Metabolism in Ovarian Cancers
Katelyn Tondo-Steele et al, 2022, Cancers CrossRef
Multiple function of lncRNA MALAT1 in cancer occurrence and progression
Faezeh Malakoti et al, 2022, Chem Biol Drug Des CrossRef